AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05349799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1 and TEOSYAL® PureSense Redensity 1 (cannula)
Description: During the first phase of the study, ubjects will be treated with TEOSYAL RHA® 1 at baseline (V1) and may receive an optional treatment at 1 month (V2).~In the exploratory phase of the study, subjects will receive additional treatment with TEOSYAL® PureSense Redensity 1 using a cannula. TEOSYAL® PureSense Redensity 1 will be administered over three sessions at 2, 3 and 4 months after baseline (respectively V3, V4 and V5).
Study NCT05055206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT-CT
Description: 99m-Technetium Sulfur Colloid will be injected prior to the scan.
Study NCT05014867 — intervention group
Intervention type: PROCEDURE
Intervention: Embryo transfer method
Description: 1. Sequential embryo transfer on day 3 and day 5 in a frozen cycle~2. Sequential embryo transfer on day 3 and day 5 in a fresh cycle~3. Sequential embryo transfer on day 3 and day 5 after performing PGS~4. Conventional Day 5 frozen embryo transfer
Study NCT05867498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent exercise
Description: Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).
Study NCT05867498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
Study NCT05890716 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI-powered ECG analysis to detect cardiac arrhythmic episodes
Description: ECG recording and processing by AI platform
Study NCT05063656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 8 weeks of gabapentin, titrated up to 20 mg/kg in 3 divided doses daily
Study NCT04949321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
Description: Magnetic Resonance Imaging with Single dose of gadobutrol (Gd-DO3A-butrol, Gadovist® 0.1 mmol/kg, 1 mmol/mL)
Study NCT06210321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prescription of escitalopram using pharmacogenetic testing
Description: Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
Study NCT05079243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Scaffold and adipose-derived stromal cell enriched fat grafts
Description: eight different solutions of fat, ASCs, scaffold and CO2 laser in dermis three different solutions of fat, ASCs and scaffold in the subcutaneous layer
Study NCT05852613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high power laser therapy (HPLT)
Description: high power laser therapy (HPLT) will be produced by A LEVELASER EZ1 EASYONE device which produces a Ga Al As CW diode laser with pulsed emission 980 nm and maximum average power 5 W with a high level of energy penetration. While the patient is in a prone position and the head slightly bends to the front, The treatment will be performed at a distance of 60-70 cm, perpendicular to the cervical region, in a pulsed mode of 4 Hz, wavelength = 980 nm, radiation power density P = 4 W in the scan phase and 2 W in the acupuncture phase and energy 840 J. Patients will receive pulsed HPLT laser treatment for 8 minutes. Scanning will be performed transversely and longitudinally to the bilateral paraspinal muscles, inter-scapular area, upper trapezius and the neck region for 6 minutes followed by 2 minutes acupuncture. Protective goggles will be used to prevent direct eye contact of the laser beam.
Study NCT05852613 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: hot pack, US for 5 min, exercise for 20 min.
Study NCT05852613 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: selected physical therapy program
Description: hot pack, US for 5 min, exercise for 20 min.
Study NCT04626167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concomitant Renal and Urinary Bladder Allograft Transplantation
Description: This is a single-center, prospective, single-group unblinded phase I study that will enroll subjects with chronic kidney disease secondary to bladder dysfunction or bladder absence that is refractory to medical treatment and requires surgical intervention to prevent long-term sequelae. Patients will undergo a cadaveric donor bladder transplant in addition to or after their kidney transplant rather than using intestinal segments for bladder reconstruction or contruction.
Study NCT00012844 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed
Study NCT00012844 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed
Study NCT05826171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Exercise Prior to Balance Training
Description: 20-30 minutes of high intensity aerobic exercise followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 weeks (16 sessions total). For the aerobic component, participants will be instructed in a 20-30-minute exercise program, using available equipment already located in the participant's home (eg. stationary cycle, elliptical trainer, etc). Exercise intensity is moderate-to-high (between 50-85% Heart Rate Reserve. Participants will be placed on a ramped protocol which increases in intensity slowly over the course of the intervention period. For the balance training component, exercises will consist of steady state, proative, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.
Study NCT05826171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Exercise Prior to Balance Training
Description: 20-30 minutes of light intensity warm-up type exercises, followed by 20-30 minutes of individualized balance training over telehealth twice weekly, for 8 week (16 sessions total). For the warm-up exercise component, exercises will consist of stretching and core training. For the balance training component, exercises will consist of steady state, proactive, and reactive balance activities that involve sensory integration of vision, proprioception, and vestibular senses throughout. Exercises will be individualized based on baseline assessment outcomes and severity of ataxia as rated by the SARAHome.~Both groups are matched for time and frequency of intervention components.
Study NCT06114667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilatory support via nasal high flow
Description: Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
Study NCT06114667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilatory support via NIV
Description: Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
Study NCT04993157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIA586
Description: FIA586 capsule
Study NCT04802577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FACT-F questionnaire
Description: The questionnaire, based on patient report outcome data in which the presence of fatique is investigated in participants.
Study NCT04802577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory
Description: The questionnaire, based on patient report outcome data in which the presence of depression is investigated in participants.
Study NCT04802577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Anxiety Inventory
Description: The questionnaire, based on patient report outcome data in which the presence of anxiety is investigated in participants.
Study NCT04802577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia severity index.
Description: The questionnaire, based on patient report outcome data in which the presence of insomnia is investigated in participants.
Study NCT04802577 — intervention group
Intervention type: OTHER
Intervention: ESSPRI
Description: The questionnaire, based on patient report outcome data in which the severity of Sjögren's syndrome is investigated in participants.
Study NCT04802577 — intervention group
Intervention type: OTHER
Intervention: ESSDAI
Description: Activity scale in which the activity of Sjögren's syndrome is evaluated based on the laboratory and imaging tests of the patients and the examination findings of the evaluator.
Study NCT04802577 — intervention group
Intervention type: OTHER
Intervention: Pain Detect Questionnaire
Description: The questionnaire, based on patient report outcome data in which the severity and extent of pain in the body are investigated in participants.
Study NCT06425042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: Participants will ingest 1g/d of NR orally during 12 weeks in parallel to a exercise training program
Study NCT06425042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will ingest 1g/d of placebo orally during 12 weeks in parallel to a exercise training program
Study NCT06060327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
Study NCT05418543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound with fine needle biopsy
Description: Patients with unresectable bile duct tumors will be investigated by either CH-EUS with FNA or conventional EUS with FNA
Study NCT03492918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Study NCT05522491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: All subjects enrolled will receive olaparib.Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
Study NCT05519722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation-focused online intervention
Description: Patients receive an expectation-focused online intervention (around 30 minutes) consisting of a video with general information about psychotherapy, a video with reports of patients' therapy experiences, questions on the content of the videos as well as open questions on personal strengths, fears and expectations in the context of therapy. This intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the psychotherapeutic process.
Study NCT04835506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: infliximab
Study NCT06086340 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib with an aromatase inhibitor therapy
Study NCT06086340 — intervention group
Intervention type: DRUG
Intervention: Aromatase Inhibitor
Description: Aromatase Inhibitor Therapy
Study NCT05266833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow diaphragmatic breathing
Description: The curriculum was based on three key breathing components that have been shown to reduce stress in adolescents: slow breathing; diaphragmatic breathing; and extended exhale breathing. Slow breathing entails breathing at a pace slower than normal breathing. Diaphragmatic breathing focuses on breaths starting from the diaphragm or abdominal areas, with abdominal, then lung, then chest expansion during the inhale and a slow, gradual, full release of air in the reverse direction on the exhale. Extended exhale breathing comprises breathing with the exhalation duration longer, often twice as long, as the inhalation.~Two versions of slow diaphragmatic extended exhale breathing were included in this study. For both, participants did the practice while seated comfortably and breathing through the nose, and were guided to increase the inhale and exhale durations over the 5 weeks. Students followed 5-minute videos for each session.
Study NCT05360862 — intervention group
Intervention type: PROCEDURE
Intervention: Prone positioning session
Description: To perform respiratory measurements before, during and after a prone positioning session.
Study NCT06462105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
Description: Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.
Study NCT05733767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.
Study NCT05733767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner Tobacco Treatment Team (NPT3)
Description: Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
Study NCT06290570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 12-Lead ECG
Description: A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.
Study NCT06290570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Apple Smart Watch Single Lead ECG
Description: A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.
Study NCT06290570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AliveCor KardiaMobile 6-Lead ECG
Description: A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.
Study NCT00000955 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tuberculin Purified Protein Derivative
Description: Administered intradermally at 5 TU per 0.1 mL
Study NCT05448885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
Study NCT05328349 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education Program
Description: After the baseline evaluation, all participants will take part in an education intervention, aiming at promoting self-management of shoulder pain, that will include two one-on-one sessions (approximately 30-45 minutes) within 2 weeks with a physiotherapist (1st session right after the baseline evaluation, 2nd session two weeks later). Participants will receive written information regarding shoulder (anatomy and function) and basic pain science and will be directed to watch a series of six educational videos on shoulder pain and function, persistent pain, physical activity, stress, sleep and eating habits. It should be noted that the objective of this study is not to assess the effectiveness of the intervention; the purpose of offering an intervention to participants is to control the intervention that will be received by them.
Study NCT04932408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the feasibility, psychosocial effects, influence and perception of exercise selection an experimental design of exercises performed at the hip and chest region.
Description: A single exposure feasibility study using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
Study NCT05767268 — intervention group
Intervention type: DEVICE
Intervention: Lokomat
Description: gait rehabilitation
Study NCT05227040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nintendo Ring Fit Adventure Exergame
Description: Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
Study 35341362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg/mL
Number of subjects: 430
Study 35341362 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 1 mg/mL
Number of subjects: 430
Study 35341362 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior vomiting
Number of subjects: 430
Study 33822385 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.5 mg/kg
Number of subjects: 27
Study 33822385 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 2.0 mg/kg
Number of subjects: 27
Study 33822385 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa 3.0 mg/kg
Number of subjects: 27
Study 33822385 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (0.5, 2.0, or 3.0 mg/kg) administered 3 times per week
Number of subjects: 27
Study 33822385 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (dose-normalized exposure)
Number of subjects: 27
Study 33822385 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (dose-normalized exposure across BMI categories)
Number of subjects: 27
Study 33244316 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA recombinant vaccine expressing HIV-B antigen (MVA-B) via transcutaneous route
Number of subjects: 20
Study 33244316 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA recombinant vaccine expressing HIV-B antigen (MVA-B) via intramuscular route
Number of subjects: 20
Study 35382694 — intervention group
Group type: EXPERIMENTAL
Intervention: Comic
Number of subjects: 1236
Study 35382694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay summary
Number of subjects: 1236
Study 35382694 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific abstract
Number of subjects: 1236
Study 32404980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (specifics not provided)
Number of subjects: 609
Study 36413516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (Body in Mind Training [BMT])
Number of subjects: 124
Study 36413516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 124
Study 36413516 — intervention group
Group type: COMPARATOR
Intervention: Active control group (quality of life [QoL])
Number of subjects: 124
Study 34188144 — intervention group
Group type: EXPERIMENTAL
Intervention: Inefficient arsenic metabolism (%iAs) among never-smokers
Number of subjects: 1395